Valsartan With HydrochlorothiazideCo-Diovan
Recommended CardiovascularRestricted benefitLater-line line
Hypertension in patients who are not adequately controlled with either hydrochlorothiazide or valsartan monotherapy.
1
Submissions
2008–08
On the record
—
ICER range
Cost-min
Cost basis
Decisions on record
- Meeting Jul 2009 Recommended Anti-hypertensive no PSD
- Meeting Nov 2008 Not recommended Hypertension no PSD
- Meeting Jul 2008 Recommended Blood pressure
Access path
- TGA registered · Co-Diovan
TGA label narrower than the PBS population
- Jul 2008Recommended · restricted
vs valsartan and hydrochlorothiazide given individually at…
- PBS listing · Restricted benefit
RecommendedDeferredNot recommended
Cost-effectiveness
Cost-minimisation analysis conducted; no ICER calculated
Decision context
Populationpatients with hypertension who are not adequately controlled with either hydrochlorothiazide or valsartan monotherapy
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Jul 2008 | Recommended · restricted | valsartan and hydrochlorothiazide given individually at equivalent doses | — | RCT, pharmacokinetic studies · mean change in blood pressure (mmHg) |
Similar precedents
Olmesartan Medoxomil With Hydrochlorothiazide82%Amlodipine (As Besylate) With Valsartan And Hydrochlorothiazide79%Amlodipine Besylate With Valsartan79%Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide75%Olmesartan Medoxomil With Amlodipine74%Telmisartan With Amlodipine71%Ramipril With Felodipine72%Lercanidipine With Enalapril71%
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to patients inadequately controlled on prior monotherapy (hydrochlorothiazide or valsartan), a later-line subset of the broad TGA hypertension indication.